Andrew Trovato

Novartis Pharma AG
Papers:
Evaluation of Late-Night Salivary Cortisol during 12 Months of Pasireotide Treatment in Patients with Cushing's Disease
Improvements in the Clinical Signs and Symptoms of Cushing's Disease Following 12 Months' Treatment with Pasireotide are Not Restricted to Patients Who Achieve UFC Control